Dantrium

NURS 2516 Clinical Medications Worksheets (You will need to make additional copies of these forms) Generic Name Trade Name Dantrium Dantrolene Peak unknown

Onset 1 wk

Classification Dose Route Time/frequency Skeletal muscle 25 mg po 0900; daily relaxants 50 mg 2100; q HS Duration For IV meds, compatibility with IV drips and /or solutions 6-12 hr N/A

Mechanism of action and indications (Why med ordered) Acts directly on skeletal muscle, causing relaxation by decreasing calcium release from sarcoplasmicreticulum in muscle cells. Prevents intense catabolic process associated with malignant hyperthermia. Muscle relaxant for spasms, constipation

Nursing Implications (what to focus on) Contraindications/warnings/interactions Women, pts > 35 yrs (increased risk of hepatotoxicity)

Interactions with other patient drugs, OTC or herbal medicines (ask patient specifically) none

Lab value alterations caused by medicine Monitor liver function frequently during therapy. Liver function abnormalities (increased AST, ALT, alkaline phosphate, bilirubin, GGTP) may require discontinuation of therapy Be sure to teach the patient the following about this medication Advise pt not to take more medication than the amount prescribed to minimize risk of hepatotoxicityand other side effects. If a dose is missed, do not take unless remembered within 1 hr. Do not double doses. May cause dizziness, drowsiness, visual disturbances, and muscle weakness. Advisept to avoid driving and other activities requiring alertness until response to drug is known. Advise pt to avoid taking other CNS depressants or alcohol concurrently with this medication. Instruct pt to notify healthcare provider if rash, itching, yellow eyes or skin color, dark urine or claycolored, bloody, or black, tarry stoolsoccur or if nausea, weakness, fatigue, or diarrhea persists. May require discontinuation of therapy. Advise pt to wear sunscreen and protective clothing to prevent photosensitivity reactions. Emphasize the importance of follow-up exams to check progress in long-term therapy and blood tests to monitor for side-effects.

Common side effects Drowsiness, muscle weakness, hepatotoxicity, diarrhea

Nursing Process- Assessment (Pre-administration assessment) Assess bowel function periodically. Persistent diarrhea may warrant discontinuation of therapy. Assess neuromuscular status and muscle spasticity before initiating therapy and periodically during it course to determine response to therapy.

Assessment Why would you hold or not give this med? Liver function abnormalities. Disruptive or dangerous side effects.

Evaluation Check after giving Relief of muscle spasm within 45 days of initial treatment.